Following our interview with Dr. Thillai about the symptoms and treatments available for Pulmonary Fibrosis, he shared how Royal Papworth Hospital hope to contribute to the success of available treatments for IPF, with the development of the HLRI and clinical research trials:

"As IPF progresses, patients can become more breathless and some patients end up being on oxygen and needing assistance with their day-to-day activities. Some of our patients are lucky enough to get a lung transplant."

At the moment, a lung transplant is the only way of actually curing lung fibrosis.

"The specialised drugs that we have can slow down the process, but they cant actually cure the disease itself"

"The drugs for Lung Fibrosis have only been around for a few years, and there are a number of new drugs that are being tested, and we are very fortunate at Royal Papworth to be a part of clinical trials looking at brand new drugs. As well as drug trials, we also do basic science research with our colleagues at the University of Cambridge in the science buildings."

"The building of the new HLRI will allow Royal Papworth to bring all of this together to do both drug trials and also do laboratory work with our colleagues to try and look for new ways of diagnosing and new ways of treating lung fibrosis."

The Heart and Lung Research Institute (HLRI) will attract some of the best researchers and academics across Europe to help in the research and improvement of cures and treatments for heart and lung disease globally.

"Here at Royal Papworth, we are have a number of research grants at the moment. Some from the pharmacutical industry, looking at new drugs, and others, for example, from the British Lung Foundation and the foundation for sarcoidosis in the United States of America."

"We hope over the next few years to make some breakthroughs in the way we diagnose this condition, but also find better ways of treating this disease."

"We are indebted to both the Royal Papworth Charity who administered the funds, as well as families of patients who passed away from lung fibrosis and have given been very generous, enabling us to do some very exciting things, including buy equipment for the ward patients. But also we have set up an education grant to allow our trainees to travel to conferences. One, for example, is traveling to Madrid to a Respiratory Society to present some research he has conducted here at Royal Papworth. So we are thankful to both the Charity and families for making that possible."

If you would like to support the research and clinical trials that could discover better treatments for Idiopathic Pulmonary Fibrosis, then please support our appeal to raise over £2.6 million in the next 2 years for the construction of the HLRI. Any donation will make a huge difference.